Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5665735 | 1.00 | CYP3A4 (0.54) | CYP3A4CYP2D6CYP2C9ALDH1A1GRIN2D | |
| SCHEMBL3620867 | 0.93 | CYP3A4 (0.60) | CYP3A4CYP2D6CYP2C9ALDH1A1GRIN2D | |
| SCHEMBL11524101 | 0.93 | CYP3A4 (0.60) | CYP3A4CYP2D6CYP2C9ALDH1A1GRIN2D | |
| SCHEMBL6635785 | 0.93 | CYP3A4 (0.60) | CYP3A4CYP2D6CYP2C9ALDH1A1GRIN2D | |
| SCHEMBL12416611 | 0.90 | CYP3A4 (0.58) | CYP3A4CYP2D6CYP2C9ALDH1A1GRIN2D | |
| SCHEMBL10346503 | 0.90 | CYP3A4 (0.58) | CYP3A4CYP2D6CYP2C9ALDH1A1GRIN2D | |
| SCHEMBL10013520 | 0.90 | ALDH1A1 (0.56) | CYP3A4CYP2D6CYP2C9ALDH1A1GRIN2D | |
| SCHEMBL1129722 | 0.89 | CYP2C9 (0.55) | CYP3A4CYP2D6CYP2C9ALDH1A1GRIN2D | |
| SCHEMBL1129724 | 0.89 | CYP2C9 (0.55) | CYP3A4CYP2D6CYP2C9ALDH1A1GRIN2D | |
| SCHEMBL25491825 | 0.88 | ALDH1A1 (0.61) | CYP2D6CYP2C9ALDH1A1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | disclosed |
| US-7915245-B2 | Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915245-B2 | Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
| US-20060188793-A1 | Adjustable Transmission Phase Shift Mask | LSI LOGIC CORPORATION (US) | 2006-08-24 | — | — | US | disclosed |
| US-7067223-B2 | Adjustable transmission phase shift mask | LSI LOGIC CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050112478-A1 | Adjustable transmission phase shift mask | LSI LOGIC CORPORATION | 2005-05-26 | — | — | US | disclosed |
| US-6841308-B1 | Adjustable transmission phase shift mask | LSI LOGIC CORPORATION (US) | 2005-01-11 | — | — | US | disclosed |
| US-4035060-A | Electro-optic device | DAINIPPON PRINTING CO., LTD (JA) | 1977-07-12 | — | — | US | disclosed |
| US-3960749-A | Liquid-crystal mixtures for use in liquid-crystal displays | INTERNATIONAL LIQUID XTAL COMPANY (US) | 1976-06-01 | — | — | US | disclosed |
| US-3944330-A | Electro-optic device | DAINIPPON PRINTING CO., LTD. (JA) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | CYP3A4 1829/4885CYP2D6 3437/4885CYP2C9 3911/4885 |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | CYP3A4 1829/4885CYP2D6 3437/4885CYP2C9 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.